GENETIC THERAPY COULD RECEIVE UP TO $18 MIL. FROM SANDOZ FOR HS-tk
GENETIC THERAPY COULD RECEIVE UP TO $18 MIL. FROM SANDOZ FOR HS-tk technology for cancer treatment, Genetic Therapy, Inc, announced June 15, Sandoz will make an upfront payment "exceeding" $6 mil. and milestone payments of up to $12 mil. under a joint product development and marketing agreement, with the possibility of subsequent HS-tk (herpes simplex thymidine kinase) products "carrying additional upfront and milestone payments if developed under the agreement," the firm noted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth